Investigation, explanation, and apology for incomplete and erroneous disclosures [6]

JAMA

Volumn 296, Issue 18, 2006, Pages 2205-

  Matteson, Eric L ^a   Bongartz, Tim ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

CANCER RISK; DRUG INDUSTRY; ERROR; INTERPERSONAL COMMUNICATION; LETTER; MEDICAL LITERATURE; PRIORITY JOURNAL;

EID: 33750685598     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.18.2205-a     Document Type: Letter

References (2)

1. Bongartz T, Sutton AJ, Sweeting MJ, Buchnan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: a systematic review and meta-analysis of rare harmful effects in randomized clinical trials. JAMA. 2006;295:2275-2285.
2. Incorrect statements on funding/support and role of the sponsors and incorrect and incomplete financial disclosures [correction to: anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.] JAMA. 2006;295:2482.